Company Overview
Company Type: Public Company
Website: www.medexus.com
Number of Employees: 98
Ticker: MDP (TSX)
Year Founded: -


Business Description
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
160.2
Market Capitalization
61.6
TEV/Total Revenue
0.9x
EBITDA
26.1
Total Enterprise Value
137.3
TEV/EBITDA
5.3x
EBIT
18.2
Cash & ST Invst.
21.7
P/Diluted EPS Before Extra
13.9x
Net Income
4.5
Total Debt
100.2
Price/Tang BV
NM
Capital Expenditure
(0.1)
Total Assets
229.2
Total Debt/EBITDA
3.8x
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Mar-31-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
0.03
0.08
0.21
0.48
0.28
Revenue (mm)
41.00
41.98
166.06
179.01
165.96
EBITDA (mm)
7.65
8.05
32.32
35.61
31.40

Forward Multiples (Current FY)

Price/Earnings
12.76x
TEV/REV
0.79x
TEV/EBITDA
4.08x
P/BV
1.16x

Non-Periodic Estimates

Recommendation
Outperform (1.57)
Target Price
4.17
Potential Upside
52.07%


Key Professionals
Name
Title
d'Entremont, Kenneth 
CEO & Director
Konrad, Marcel 
Chief Financial Officer
Byers, Tina 
Executive of Investor Relations
Wildgoose Brown, Ian C.
General Counsel & Corporate Secretary
Poncy, Bill 
Senior Vice President of Commercial Operations - United States
Peters, Brian 
Vice President of Sales & Marketing - United States

Key Board Members
Name
Title
Mueller, Michael Peter
Independent Chairman
d'Entremont, Kenneth 
CEO & Director
Gravel, Benoit 
Independent Director
Taddese, Menassie 
Independent Director
Garges, Harmony Phillips
Independent Director
Nelson, Stephen William
Independent Director
Phelan, Nancy R.
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
35 Nixon Road Unit 1 | Bolton, ON | L7E 1K1 | Canada
Phone: 877-633-3987   

Current and Pending Investors
9346-4626 Québec Inc., Bloom Burton Healthcare Structured Lending Fund II, CorpoSana Capital Inc. (Jean Pelchat), GoodWood Inc., Knight Therapeutics Inc. (TSX:GUD), Lumira Ventures, Senvest Capital Inc. (TSX:SEC)

Prior Investors
CIME Gestion du FIER Montestrie Capital Inc., FIER Longueuil, FIER-Montestrie Capital S.E.C.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 2.74
Market Cap (mm)
56.3
Open
 2.90
Shares Out. (mm)
20.6
Previous Close
 2.74
Float %
83.8%
Change on Day
(0.26)
Shares Sold Short (mm)
-
Change % on Day
(8.7)%
Dividend Yield %
-
Day High/Low
 2.91/ 2.66
Diluted EPS Excl. Extra Items
0.22
52 wk High/Low
 3.53/ 0.98
P/Diluted EPS Before Extra
12.70x
Volume (mm)
0.06
Avg 3M Dly Vlm (mm)
0.05
Beta 5Y
1.66


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
TSX:MDP - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Worldwide rights to IXINITY
As of February 28, 2020, Worldwide rights to IXINITY was acquired by Medexus Pharmaceuticals Inc. Worldwide rights to IXINITY comprises the rights to IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes.

United States and Canada
Biotechnology
-
-
-
Medac Pharma, Inc.
Medac Pharma, Inc. engages in developing and commercializing medicines for autoimmune diseases and cancer. The company is headquartered in Chicago, Illinois. Medac Pharma, Inc. operates as a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH. As of October 16, 2018, Medac Pharma, Inc. operates as a subsidiary of Pediapharm Inc.

United States and Canada
Pharmaceuticals
-
-
-
Medexus Inc.
Medexus Inc. engages in the distribution of pharmaceutical products. The company was founded in 2000 and is based in Bolton, Canada. As of October 16, 2018, Medexus Inc. operates as a subsidiary of Pediapharm Inc.

United States and Canada
Health Care Distributors
-
-
-
Chelsea Acquisition Corporation
As of December 24, 2013, Chelsea Acquisition Corporation was acquired by Pediapharm Inc., in a reverse merger transaction. Chelsea Acquisition Corporation does not have significant operations. It intends to identify and evaluate corporations, businesses, or assets for acquisition and once identified and evaluated, to negotiate an acquisition or participation subject to receipt of shareholder and regulatory approval. The company was formerly known as Goldhold Corporation and changed its name to Chelsea Acquisition Corporation in September 2011. Chelsea Acquisition Corporation was incorporated in 2011 and is based in Calgary, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00
Medexus Pharma Inc.
Medexus Pharma Inc. is a pharmaceuticals company. It is based in Chicago, Illinois.

United States and Canada
Pharmaceuticals
7.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-5-2023
-
Public Offering
Target
Medexus Pharmaceuticals Inc. (TSX:MDP)


7.32
Jul-28-2021
-
Shelf Registration
Target
Medexus Pharmaceuticals Inc. (TSX:MDP)


79.55
Jul-20-2021
-
Shelf Registration
Target
Medexus Pharmaceuticals Inc. (TSX:MDP)


78.45
Feb-2-2021
Feb-23-2021
Public Offering
Target
Medexus Pharmaceuticals Inc. (TSX:MDP)


22.46
Feb-28-2020
Feb-28-2020
Merger/Acquisition
Buyer
Worldwide rights to IXINITY
Medexus Pharmaceuticals Inc. (TSX:MDP)
Aptevo Therapeutics Inc. (NasdaqCM:APVO)
41.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-28-2023
Client Announcements
Medexus Pharmaceuticals and Medac GmbH Agree to Amend US Treosulfan Agreement
Sep-21-2023
Shareholder/Analyst Calls
Medexus Pharmaceuticals Inc. - Shareholder/Analyst Call
Sep-21-2023
Annual General Meeting
Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023
Sep-05-2023
Composite Units Offerings
Medexus Pharmaceuticals Inc. has announced a Composite Units Offering in the amount of CAD 10.000205 million.
Aug-17-2023
Product-Related Announcements
Medexus Pharmaceuticals Announces the Presentation of Data from Phase 3/4 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of IXINITY

Competitors
Antares Pharma, Inc.

M&A Advisors
Bloom Burton Securities Inc., Burstall LLP, Gowling WLG International Limited, Munsch Hardt Kopf & Harr, P.C.


Advisors
Most Recent Auditor
PricewaterhouseCoopers LLP
M&A Advisors
Bloom Burton Securities Inc., Burstall LLP, Gowling WLG International Limited, Munsch Hardt Kopf & Harr, P.C.
Private Placement Advisors
Bloom Burton & Co. Inc., Bloom Burton Securities Inc., Cormark Securities Inc., Laurentian Bank Securities, Inc., Research Capital Corporation, Richardson GMP Limited, Investment Banking Arm
Public Offering Advisors
Blake, Cassels & Graydon LLP, PricewaterhouseCoopers LLP, Canada, Troutman Pepper Hamilton Sanders LLP


Most Recent Auditor
PricewaterhouseCoopers LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

04:12 AM
MDP
Medexus Pharmaceuticals Inc 2023_10_05
Reports
15
CFRA Equity Research

Oct 01, 2023 08:39 AM
MDP
Medexus Pharmaceuticals Inc.
Reports
9
S&P Global Compustat

Sep 07, 2023 04:09 AM
MDP
Medexus Pharmaceuticals Inc 2023_09_07
Reports
15
Raymond James Ltd.
Sarugaser, Rahul
Sep 06, 2023 07:01 AM
MDP
MDP | Maint. $4 TP | Lifting $38 mln Conv. Debt Overhang: $18 mln Credit + $10 mln Eq. Raise + Cash
EPS Estimates*
9
Echelon Wealth Partners Inc.
Quenneville, Stefan
Sep 06, 2023 05:11 AM
MDP
MDP - $18M Secured Under Existing Credit Facility and Cash Guidance Should Settle Concerns Over Convertible Debt Repayment; Maintaining Spec. Buy Rating and PT
Notes
5
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Aug 29, 2023 06:00 PM
MDP
Rating Update for Medexus Pharmaceuticals Inc
EPS Estimates*
3
Raymond James Ltd.
Sarugaser, Rahul
Aug 18, 2023 11:15 AM
MDP
MDP | Overlooked CY24 Catalyst: IXINITY's Potential Expansion into Pediatric Population
Reports
8
Roth MKM
Henry, Scott Robert
Aug 14, 2023 07:37 AM
MDP
MEDXF: FY1Q24 Recap - Upside Continues; PT to $3.50
EPS Estimates*
7
Raymond James Ltd.
Sarugaser, Rahul
Aug 10, 2023 03:25 PM
MDP
MDP | Cash Accruing Nicely to Settle Conv. Debt in Oct. | 1Q24: Big Rev., Again | Treo Resub.: 1H24
EPS Estimates*
10
Research Capital Corporation
Uddin, Andre
Aug 10, 2023 05:36 AM
MDP
Strong Q1 - The Base Continues to Build
EPS Estimates*
10


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


d'Entremont, Kenneth 

1,461,869

7.11

4.8

Aug-09-2023


GoodWood Inc.

1,038,716

5.05

3.4

Apr-30-2023


Nelson, Stephen William

547,079

2.66

1.8

Sep-29-2023


Lumira Ventures

432,063

2.10

1.4

Aug-05-2022


Konrad, Marcel 

80,021

0.39

0.3

Aug-14-2023


Gulfo, Adele M. 

54,930

0.27

0.2

Sep-22-2023


Gravel, Benoit 

53,158

0.26

0.2

Sep-29-2023


Adelman, Michael David

28,800

0.14

0.1

Aug-14-2023


Perritt Capital Management, Inc.

25,000

0.12

0.1

Jul-31-2023


Wildgoose Brown, Ian C.

20,634

0.10

0.1

Aug-14-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Konrad, Marcel 
80,021
50,601
d'Entremont, Kenneth 
1,461,869
25,310
Perritt Capital Management, Inc.
25,000
25,000
Wildgoose Brown, Ian C.
20,634
20,634
Gulfo, Adele M. 
54,930
16,546

Top Sellers
Sellers
Common Stock Equivalent Held
Change
GoodWood Inc.
1,038,716
(295,554)
Mueller, Michael Peter
0
(79,179)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Cuvposa, Distribution of Gleolan, Distribution of Treosulfan, Metoject, Rasuvo, Relaxa, Rupall, Treosulfan, Trispan


Upcoming Events
Date/Time
Type
Nov-09-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-28-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
News Releases
34 KB
Sep-28-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
Documents Affecting the Rights of Security Holders
200 KB
Sep-21-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
News Releases
34 KB
Sep-05-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
News Releases
115 KB
Sep-05-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
News Releases
36 KB
Sep-05-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
Short Form Prospectus (NI 44-101)
583 KB
Sep-05-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
Short Form Prospectus (NI 44-101)
495 KB
Sep-05-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
Short Form Prospectus (NI 44-101)
63 KB
Sep-05-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
Short Form Prospectus (NI 44-101)
161 KB
Sep-05-2023
Medexus Pharmaceuticals Inc. (TSX:MDP)
SEDAR
Short Form Prospectus (NI 44-101)
121 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Mueller, Michael Peter (Independent Chairman)
Sep-22-2023
Common Shares
10,691
32,726
Derivative Exercise and Retained Stock
13.50
Multiple
Gravel, Benoit  (Independent Director)
Sep-22-2023
Common Shares
10,644
32,583
Derivative Exercise and Retained Stock
25.04
Multiple
Gulfo, Adele M.  (Former Independent Director)
Sep-22-2023
Common Shares
16,546
50,649
Derivative Exercise and Retained Stock
43.11
Multiple
Nelson, Stephen William (Independent Director)
Sep-22-2023
Common Shares
10,691
32,726
Derivative Exercise and Retained Stock
1.99
Multiple
Garges M.D., M.P.H., Harmony Phillips (Independent Director)
Sep-22-2023
Common Shares
13,259
40,587
Derivative Exercise and Retained Stock
New
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Mueller, Michael Peter
Independent Chairman
877-633-3987
-
mike.mueller@blcgf.ca
d'Entremont, Kenneth 
CEO & Director
905-676-0003
-
ken.dentremont@medexus.com
Gravel, Benoit 
Independent Director
877-633-3987
-

Taddese, Menassie 
Independent Director
877-633-3987
-

Garges, Harmony Phillips
Independent Director
877-633-3987
-

Nelson, Stephen William
Independent Director
877-633-3987
-

Phelan, Nancy R.
Independent Director
877-633-3987
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
d'Entremont, Kenneth 
CEO & Director
905-676-0003
-
ken.dentremont@medexus.com
Konrad, Marcel 
Chief Financial Officer
312-548-3139
-
marcel.konrad@medexus.com
Byers, Tina 
Executive of Investor Relations
905-330-3275
-
tina@adcap.ca
Wildgoose Brown, Ian C.
General Counsel & Corporate Secretary
877-633-3987
-

Poncy, Bill 
Senior Vice President of Commercial Operations - United States
877-633-3987
-

Peters, Brian 
Vice President of Sales & Marketing - United States
877-633-3987
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
